Gastric cancer treatment in the world: Germany

Abstract

Epidemiologically, around 15,500 persons per year contract gastric cancer with continuously decreasing incidence and a 5-year survival rate of only 30% to 35%. Contrary to the Asian countries, there are no prevention programs for gastric cancer in Germany, which leads to the disease frequently being diagnosed in locally advanced stages and predominantly being treated with multimodal therapy concepts. Complete (R0) resection is the therapy of choice for resectable gastric cancer. Special forms of gastric cancer that are limited to the mucosa can be endoscopically resected with a curative intent. Systematic D2 lymphadenectomy (LAD) plays a decisive role in the management of local advanced tumors because it significantly contributes to the reduction of tumor-related death and both local and regional relapse rates. Perioperative chemotherapy improves prognosis in the advanced stages, whereas palliative chemotherapy is normally indicated for metastatic diseases. Standardized resection procedures and the use of individualized multimodal therapy concepts have led to improvement in the 5-year survival rate.

Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance

“…It has the characteristics of easy invasion and metastasis, and a very low early diagnosis rate [ 2 ]. Despite the gradual decline in incidence and mortality of gastric cancer in recent years, the prognosis of patients with gastric cancer has not been significantly improved [ 3 ]. Thus, to explore biomarkers that can aid in the prognosis of gastric cancer not only would help clinicians predict prognosis and establish individualized treatment plans, but also would help clarify the mechanism of gastric carcinogenesis and development, which has important significance for formulating the treatment strategy of gastric cancer.…”

Gastrointestinale Tumoren. Hoher medizinischer Bedarf für neue Therapieoptionen

“…Die Etablierung von Screening-Programmen hat insbesondere in Korea und Japan dazu geführt, dass das Magenkarzinom oftmals noch im frühen Stadium entdeckt und behandelt werden kann [6,7]. Dahingegen befindet sich mehr als die Hälfte der in Deutschland erstdiagnostizierten Magenkarzinome bereits im lokal fortgeschrittenen Stadium (cT3 oder höher) [8].…”

Comparison of Functional Outcomes between Functional Jejunal Interposition and Conventional Roux-en-Y Esophagojejunostomy after Total Gastrectomy for Gastric Cancer

“…Radical resection is widely considered as the most effective treatment for advanced gastric cancer [3,4]. In China, advanced gastric cancer with extensive invasion of gastric wall is more common as compared with other Asian countries, and most of these patients usually have to undergo total gastrectomy, regardless of open or laparoscopic approach, to achieve complete (R0) resection [5]. However, the reconstruction of digestive tract after total gastrectomy, which is almost exclusively represented by conventional Roux-en-Y esophagojejunostomy in China, is linked with various early and late postoperative complications and discomfort, such as dietary restriction, reflux esophagitis, dumping syndrome, anastomotic stenosis, and malnutrition [6].…”